Information for Patients
If you’re a patient suffering from an infection caused by C.difficile or a different type of microbiome mediated condition then you may be able to access our products through your doctor.
Your microbiome and you
Your microbiome plays a crucial role in your health. When this community of bacteria and other microorganisms are disturbed or out of balance, you may experience negative effects.
This can happen when antibiotics disrupt the normal activity and composition of the gut microbiome. This can lead to certain opportunistic bacteria becoming dominant and causing disease.
Clostridiodes difficile (C.diff) is one such bacteria which typically does not cause disease in healthy individuals with a robust microbiome. However, when certain criteria are met, specifically a disturbance to the healthy microbiome, the bacteria finds the appropriate conditions to multiply in the colon, which ultimately results in a C.difficile infection (CDI).
Patients with CDI can often be successfully treated with antibiotics; however, there is a high risk of the infection returning. When patients suffer from multiple recurrences, this has a significant impact on both their quality of life and on the healthcare systems they go to for treatment.
It is thought that patients suffer from recurring infections because the treatments that are currently available do not treat the underlying microbial imbalance.
FMT as a treatment
Medical treatments that restore diversity in the gut microbiome could be the best option for patients suffering from hard to treat infections caused by gut-dwelling bacteria. To date, the most successful of these treatments is Faecal Microbiota Transplantation (FMT).
FMT involves the transfer of rigorously screened stool from a healthy donor into the intestinal tract of the person suffering from infection.
FMT is a National Institute for Health and Care Excellence (NICE) approved treatment for recurrent CDI with cure rates of ~90% reported widely across the medical literature. FMT has also shown promise in clinical trials for other diseases, such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).
Demand for FMT is growing rapidly, but until recently, there was no product for doctors to use in the treatment. After identifying this unmet clinical need, EnteroBiotix has developed pre-screened, off-the-shelf and ready-to-use faecal microbiota products that can be used by doctors in FMT.
For further information, please download our patient information leaflet.